Jessica L Mega

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2221-8. 2011
  2. doi request reprint Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 112:472-8. 2013
  3. doi request reprint Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thro
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 61:1853-9. 2013
  4. doi request reprint Antithrombotic therapy: triple therapy or triple threat?
    Jessica Mega
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Hematology Am Soc Hematol Educ Program 2012:547-52. 2012
  5. doi request reprint Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)
    Jessica L Mega
    Brigham and Women s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA
    Circulation 121:1809-17. 2010
  6. pmc Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 376:1312-9. 2010
  7. doi request reprint Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
  8. doi request reprint Identification of genetic variants associated with response to statin therapy
    Jessica L Mega
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:1310-5. 2009
  9. ncbi request reprint Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    J L Mega
    TIMI Study Group, Boston, MA, USA
    Lancet 374:29-38. 2009
  10. doi request reprint Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:2553-60. 2009

Detail Information

Publications28

  1. doi request reprint Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2221-8. 2011
    ..Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel...
  2. doi request reprint Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 112:472-8. 2013
    ..Thus, the addition of rivaroxaban 2.5 mg twice daily offers a more favorable balance of efficacy and safety in patients with recent acute coronary syndromes...
  3. doi request reprint Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thro
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 61:1853-9. 2013
    ..The present analysis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) patients, in whom anticoagulant therapy has been of particular interest...
  4. doi request reprint Antithrombotic therapy: triple therapy or triple threat?
    Jessica Mega
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Hematology Am Soc Hematol Educ Program 2012:547-52. 2012
    ..Ultimately, selecting the most favorable antithrombotic strategy is going to involve weighing the risks and benefits for each patient...
  5. doi request reprint Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)
    Jessica L Mega
    Brigham and Women s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA
    Circulation 121:1809-17. 2010
    ..In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women...
  6. pmc Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 376:1312-9. 2010
    ..We also assessed the effect of genotype on the pharmacodynamic and pharmacokinetic properties of these drugs in healthy individuals...
  7. doi request reprint Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
    ..Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome...
  8. doi request reprint Identification of genetic variants associated with response to statin therapy
    Jessica L Mega
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:1310-5. 2009
    ..The purpose of this study was to test the association between polymorphisms in genes involved in either LDL cholesterol (LDL-C) metabolism or statin pharmacokinetics and LDL-C reduction with statins...
  9. ncbi request reprint Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    J L Mega
    TIMI Study Group, Boston, MA, USA
    Lancet 374:29-38. 2009
    ..However, its use after acute coronary syndromes has not been investigated. In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing regimen...
  10. doi request reprint Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:2553-60. 2009
    ..The effect of CYP polymorphisms on the clinical outcomes in patients treated with prasugrel remains unknown...
  11. doi request reprint Cytochrome p-450 polymorphisms and response to clopidogrel
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 360:354-62. 2009
    ..Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function...
  12. ncbi request reprint Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2422-9. 2008
    ..We sought to test the prognostic performance of thrombus precursor protein (TpP) in patients presenting with an acute coronary syndrome (ACS)...
  13. ncbi request reprint Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 115:2822-8. 2007
    ..The safety and efficacy of pharmacological reperfusion therapy in women with ST-elevation myocardial infarction are of particular interest...
  14. ncbi request reprint Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy
    Jessica L Mega
    TIMI Thrombolysis in Myocardial Infarction Study Group, Boston, Massachusetts 12114, USA
    J Thromb Thrombolysis 22:71-6. 2006
    ..While statins have been shown to reduce cerebrovascular events (CVE), the relationship between cholesterol, C-reactive protein (CRP), and CVE in patients treated with different statin strategies is still being explored...
  15. ncbi request reprint Dynamic aortic obstruction in a patient with acute type B dissection
    Jessica L Mega
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cardiol Rev 14:151-4. 2006
    ..In this case presentation, we highlight the unusual physiology exemplified by this case and explore contemporary management strategies for complicated type B aortic dissection, including surgery and catheter-based techniques...
  16. pmc Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    JAMA 304:1821-30. 2010
    ..Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes...
  17. doi request reprint Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-c
    C Michael Gibson
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 161:815-821.e6. 2011
    ..9%] vs 62/1160 [5.5%]; hazard ratio 0.69, [95% CI 0.50-0.96], P = .027). Two candidate doses of rivaroxaban were selected for further evaluation in a pivotal phase 3...
  18. ncbi request reprint B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ....
  19. doi request reprint Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    Michelle L O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 374:989-97. 2009
    ..Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel...
  20. ncbi request reprint Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
    Jessica L Mega
    TIMI Study Group, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 149:846-50. 2005
    ....
  21. doi request reprint Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 162:518-26.e5. 2011
    ..The aims of this analysis were to evaluate the impact of smoking on the antiplatelet effect of clopidogrel and prasugrel and to test the potential interaction of smoking with the treatment effect of these drugs...
  22. ncbi request reprint Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:438-45. 2006
    ..The purpose of this study was to conduct a meta-analysis that compares the reduction of cardiovascular outcomes with high-dose statin therapy versus standard dosing...
  23. doi request reprint Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
    Oluseyi Ojeifo
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    JACC Cardiovasc Interv 6:1275-81. 2013
    ..This study sought to evaluate the clinical relevance of potential clopidogrel drug-drug interactions...
  24. pmc Interaction between cigarette smoking and clinical benefit of clopidogrel
    Nihar R Desai
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 53:1273-8. 2009
    ..The aim of this study was to examine the interaction between cigarette smoking and the clinical efficacy of clopidogrel in ST-segment elevation myocardial infarction (STEMI)...
  25. ncbi request reprint Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial
    Bram J Geller
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA, USA
    J Thromb Thrombolysis 37:310-6. 2014
    ..30). In this study of patients early after ACS undergoing intensive secondary preventive therapy, IgM anti-PC titers did not exhibit a significant relationship with cardiovascular outcomes. ..
  26. ncbi request reprint The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome
    Amy Sarma
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA
    J Am Heart Assoc 3:e000784. 2014
    ..Observational studies have raised concerns that high-potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy...
  27. pmc Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci
    Richa Saxena
    Center for Human Genetic Research, Massachusetts General Hospital, Boston, 02114, USA
    Am J Hum Genet 90:410-25. 2012
    ....
  28. ncbi request reprint Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women s Hospital, Boston, USA
    N Engl J Med 357:2167-78. 2007